Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
Pharmacokinetics
dosing optimization
therapeutic drug monitoring
Journal
United European gastroenterology journal
ISSN: 2050-6406
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
11
12
2018
accepted:
19
02
2019
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
19
7
2019
Statut:
ppublish
Résumé
The relationship between vedolizumab trough levels and combined endoscopic and clinical remission is unknown. To compare vedolizumab trough levels in patients with and without combined remission within the first year of treatment. We prospectively collected vedolizumab trough levels in 51 consecutive patients (28 Crohn's disease (CD) and 23 ulcerative colitis (UC)) before all infusions up to week 22, and at weeks 38 and 54, with concentrations measured after study completion. Centrally read endoscopy was performed at a median of 46 weeks. The primary outcome was combined endoscopic (CD: Simple endoscopic score for CD (SES-CD) < 4 without ulceration; UC: Mayo endoscopic subscore ≤ 1) and clinical remission (CD: resolution of abdominal pain; UC: resolution of rectal bleeding; both: resolution of altered bowel habit). Median vedolizumab trough levels at weeks 6 (25.7 vs 15.6 µg/mL; Early vedolizumab trough levels predicted combined endoscopic and clinical remission highlighting their possible use in clinical practice.
Sections du résumé
Background
The relationship between vedolizumab trough levels and combined endoscopic and clinical remission is unknown.
Objective
To compare vedolizumab trough levels in patients with and without combined remission within the first year of treatment.
Methods
We prospectively collected vedolizumab trough levels in 51 consecutive patients (28 Crohn's disease (CD) and 23 ulcerative colitis (UC)) before all infusions up to week 22, and at weeks 38 and 54, with concentrations measured after study completion. Centrally read endoscopy was performed at a median of 46 weeks. The primary outcome was combined endoscopic (CD: Simple endoscopic score for CD (SES-CD) < 4 without ulceration; UC: Mayo endoscopic subscore ≤ 1) and clinical remission (CD: resolution of abdominal pain; UC: resolution of rectal bleeding; both: resolution of altered bowel habit).
Results
Median vedolizumab trough levels at weeks 6 (25.7 vs 15.6 µg/mL;
Conclusion
Early vedolizumab trough levels predicted combined endoscopic and clinical remission highlighting their possible use in clinical practice.
Identifiants
pubmed: 31316778
doi: 10.1177/2050640619840211
pii: 10.1177_2050640619840211
pmc: PMC6620872
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antibodies, Monoclonal, Humanized
0
Biomarkers
0
vedolizumab
9RV78Q2002
Types de publication
Journal Article
Langues
eng
Pagination
741-749Références
Clin Gastroenterol Hepatol. 2014 Aug;12(8):1246-56.e6
pubmed: 24534550
Aliment Pharmacol Ther. 2018 Feb;47(4):478-484
pubmed: 29210094
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8
pubmed: 29704680
Inflamm Bowel Dis. 2018 Sep 15;24(10):2266-2271
pubmed: 29718327
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
Aliment Pharmacol Ther. 2015 Nov;42(10):1200-10
pubmed: 26388424
N Engl J Med. 2013 Aug 22;369(8):711-21
pubmed: 23964933
Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2
pubmed: 29935327
J Crohns Colitis. 2016 Dec;10(12):1437-1444
pubmed: 27252400
Aliment Pharmacol Ther. 2018 Apr;47(7):906-912
pubmed: 29384209
Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7
pubmed: 29223444
Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493
pubmed: 29751166
Gut. 2019 Jan;68(1):178-179
pubmed: 29331941
Inflamm Bowel Dis. 2017 Dec;23(12):2202-2208
pubmed: 29140943
Gut. 2018 Jan;67(1):43-52
pubmed: 27802155
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Crohns Colitis. 2017 Aug 1;11(8):921-929
pubmed: 28333288
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1750-1757.e3
pubmed: 27890854
Gut. 2019 Jan;68(1):25-39
pubmed: 29730603
Gastroenterology. 2014 Sep;147(3):618-627.e3
pubmed: 24859203
Aliment Pharmacol Ther. 2015 Jan;41(1):77-86
pubmed: 25348809
Scand J Gastroenterol. 2018 Jun;53(6):670-676
pubmed: 29560811
Inflamm Bowel Dis. 2019 Feb 21;25(3):580-586
pubmed: 30165638
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Dig Dis Sci. 2018 Sep;63(9):2419-2429
pubmed: 29372476